Last verified: 2026-03-01. Reviewed by Angelica Bottaro.
Known For: Part of Mindpath Health, the national psychiatry group operating since 1995 with 500+ clinicians; provides FDA-cleared TMS for treatment-resistant depression and OCD alongside esketamine, full-service psychiatry, and therapy, and is in-network with most major insurers.
| Location | Irvine, California |
| Address | 3 Corporate Park Suite 170 Irvine, CA 92606 |
| Phone | 855-501-1004 |
| Website | mindpath.com |
| Treatments | TMS therapy (transcranial magnetic stimulation) |
| Protocols | Standard rTMS |
| Conditions Treated | Treatment-resistant depression (TRD) · OCD · Smoking cessation |
| Insurance | Most major commercial plans, Medicare Part B, and Tricare typically cover TMS for treatment-resistant depression after prior authorization — verify with this clinic. |
| Cost | $300–500/session cash; $0–250/session typical insurance copay |
| Course | 36 sessions over 6–9 weeks (standard rTMS) |
HealingMaps Take: A TMS-focused practice in Irvine, CA for treatment-resistant depression and FDA-cleared adjacent indications. Verify the specific device, available protocols, and prior-authorization handling on your consult call.
Market Position: Standard transcranial magnetic stimulation is offered at this Irvine, CA location for treatment-resistant depression as covered by most major insurance plans after prior authorization.
This clinic offers standard 10 Hz rTMS (19–37 minutes per session), the most common TMS protocol and FDA-cleared for treatment-resistant depression, anxious depression, and adolescent MDD (ages 15–21). For Deep TMS, iTBS (3-min), or accelerated SAINT-style protocols, ask the clinic directly during your consult call. See our complete TMS therapy guide for a full device and protocol comparison.
Cash-pay TMS sessions in Irvine, CA typically run $300 to $500 per session, with the full 36-session course costing $7,200 to $15,000. Premium-metro clinics (NYC, San Francisco, Los Angeles, Boston) charge 30 to 50 percent more. With insurance, copays typically run $0 to $250 per session depending on your deductible status; most patients with employer-sponsored PPO plans pay $500 to $3,000 out-of-pocket for a full course. Many independent clinics offer 10 to 25 percent package discounts for cash-pay patients. TMS is HSA- and FSA-eligible. Contact this clinic directly for their specific cash-pay rates and in-network status with your insurer.
Most major commercial insurance plans (BCBS, Aetna, Cigna, UnitedHealthcare, Anthem, Humana), Medicare Part B, and Tricare cover TMS for treatment-resistant major depressive disorder. UnitedHealthcare typically requires 3 failed antidepressant trials; most other carriers require 2. Pre-authorization is mandatory across all major carriers. Coverage for off-label conditions (PTSD, fibromyalgia, bipolar depression, migraine) is rarely approved. Contact this clinic to verify in-network status with your specific insurer and to learn about their prior-authorization handling.
The “TMS dip” is a patient-coined term for temporary worsening of mood or symptom intensification that some patients experience roughly mid-course (commonly between sessions 10 and 20) before clinical improvement begins. It’s not a sign that TMS is failing — it usually resolves with continued treatment. If you experience the dip, tell your clinician immediately. They may adjust intensity, frequency, or coil position. Importantly, dropping out before session 20 substantially reduces overall response rate. Patients who push through the mid-course dip generally have better outcomes than those who quit early.
Yes. TMS requires no anesthesia, no sedation, and no IV access. Patients drive themselves to sessions, return to work, school, or normal activities immediately afterward, and need no chaperone or recovery period. This is the single largest patient-experience advantage TMS holds over ketamine therapy and ECT. Many patients schedule sessions on lunch breaks. The only post-session sensation is mild scalp tenderness for the first few sessions, which decreases substantially as scalp nerves desensitize.
Devices vary across TMS clinics — common options include NeuroStar (figure-8 coil, market leader), BrainsWay Deep TMS (H-coil family, only standalone FDA OCD clearance), MagVenture (Cool-B65, supports the 3-min iTBS protocol marketed as Express TMS), Magstim (Horizon with StimGuide navigation), and Nexstim (MRI-guided NBT). The device determines what conditions can be treated on-label. For OCD, only BrainsWay Deep TMS H7 has a standalone FDA clearance. For adolescents 15–21, only NeuroStar (since March 2024) and BrainsWay (since November 2025) hold the relevant indications. Ask the clinic which device they operate before booking.
Possibly — but only BrainsWay Deep TMS using the H7 coil holds a standalone FDA clearance for OCD (granted via the De Novo pathway in 2018). MagVenture’s Cool D-B80 has an OCD adjunct clearance. Standard NeuroStar (figure-8 coil) is not FDA-cleared for OCD. Confirm with this clinic specifically which device they use for OCD treatment. The full OCD course is 29 sessions over 6 weeks with symptom-provocation protocols.

People with various treatment-resistant disorders can find symptom relief with transcranial magnetic stimulation (TMS) therapy at MindPath Irvine. The health center utilizes TMS to help heal patients from their symptoms of depression and OCD. It can also be used as a smoking cessation device. Often, these disorders are difficult to treat, and TMS can help bridge the gaps in care where traditional medicine has failed.
The MindPath Irvine team is dedicated to collaboration. Their clinicians, technicians, and patient navigators work closely with each patient, making healing a team effort. The TMS experience provides patients with the chance to find hope for a brighter and symptom-free future.
Learn more about this treatment:
Leave a Reply